A Study Evaluating the Effects of GLPG3970 Given as Oral Treatment for 12 Weeks in Adults With Systemic Lupus Erythematosus

PHASE1TerminatedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

December 28, 2020

Primary Completion Date

October 6, 2021

Study Completion Date

October 6, 2021

Conditions
Systemic Lupus Erythematosus
Interventions
DRUG

GLPG3970 film-coated tablet

GLPG3970 for oral administration

DRUG

Placebo film-coated tablet

Placebo for oral administration

Trial Locations (14)

1612

UMHAT Sv. Ivan Rilski EAD, Sofia

2025

ARENSIA Exploratory Medicine Phase I Unit, Chisinau

4002

UMHAT-Plovdiv AD, Plovdiv

5800

Medical center Medconsult Pleven, Pleven

8041

Hospital de la Santa Creu i Sant Pau, Barcelona

21028

N.I.Pirogov Vinnytsia Reg Council, Vinnytsia

21029

SRI of Invalid Rehabilitation, Vinnytsia

30363

Centrum Medyczne Plejady, Krakow

50088

FutureMeds sp. Z o. o., Wroclaw

65026

Multidisciplinary Medical Center of Odesa National Medical University, Odesa

69600

LLC Suchasna klinika, Zaporizhzhia

85168

Szpital Uniwersytecki nr 2 im.dr J. Biziela, Bydgoszcz

00874

Medycyna Kliniczna, Warsaw

01135

Medical Centre of Ltd Liability Comp, Kyiv

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Galapagos NV

INDUSTRY